E2F1 and breast cancer: Li et al. [46] found that METTL3 is highly expressed in ADR-resistant BC cells and upregulates MALAT1 through m6A modification, which, in turn, recruits E2F transcription factor 1(E2F1) to activate anterior gradient 2 (AGR2) transcription and increases ADR resistance in BC cells.